149 related articles for article (PubMed ID: 15896457)
1. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin.
To KK; Ho YP; Au-Yeung SC
Cancer Lett; 2005 Jun; 223(2):227-37. PubMed ID: 15896457
[TBL] [Abstract][Full Text] [Related]
2. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin.
To KK; Wang X; Yu CW; Ho YP; Au-Yeung SC
Bioorg Med Chem; 2004 Sep; 12(17):4565-73. PubMed ID: 15358284
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Yu CW; Li KK; Pang SK; Au-Yeung SC; Ho YP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1686-91. PubMed ID: 16386904
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.
To KK; Ho YP; Au-Yeung SC
Anticancer Drugs; 2005 Sep; 16(8):825-35. PubMed ID: 16096430
[TBL] [Abstract][Full Text] [Related]
5. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles.
To KK; Au-Yeung SC; Ho YP
Anticancer Drugs; 2006 Jul; 17(6):673-83. PubMed ID: 16917213
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
8. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
9. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes.
Pang SK; Yu CW; Au-Yeung SC; Ho YP
Biochem Biophys Res Commun; 2007 Nov; 363(1):235-40. PubMed ID: 17868646
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
11. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
Ho YP; To KK; Au-Yeung SC; Wang X; Lin G; Han X
J Med Chem; 2001 Jun; 44(13):2065-8. PubMed ID: 11405643
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of [Pt(pyr)(N-Etlm)Cl4].
Massacesi M; Matovic Z; Ponticelli G
Farmaco; 1993 Sep; 48(9):1327-30. PubMed ID: 8259989
[TBL] [Abstract][Full Text] [Related]
15. Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells.
Pang SK; Yu CW; Guan H; Au-Yeung SC; Ho YP
Oncol Rep; 2008 Nov; 20(5):1269-76. PubMed ID: 18949432
[TBL] [Abstract][Full Text] [Related]
16. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
17. In vitro histoculture drug response assay and in vivo blood chemistry of a novel Pt(IV) compound, K104.
Kwon YE; Park JY; Kim WK
Anticancer Res; 2007; 27(1A):321-6. PubMed ID: 17352249
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cisplatin, carboplatin, etoposide and human hepatocyte growth factor on the colony formation of four human liver cancer cell lines].
Seshimo K; Hamasaki K; Gohda E; Orita K; Namba M
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1967-72. PubMed ID: 8215470
[TBL] [Abstract][Full Text] [Related]
19. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization and antitumor activity of new type binuclear platinum(II) complexes.
Zhang J; Liu L; Gong Y; Zheng X; Yang M; Cui J; Shen S
Eur J Med Chem; 2009 May; 44(5):2322-7. PubMed ID: 18524422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
